Aclaris Therapeutics Announces FDA Fast Track Designation For Modzatinib In Moderate To Severe Lichen Planus; Phase 2b Trial Initiation Expected In Q4 2026

Benzinga Newsdesk www.benzinga.com Positive 77.1%

Neg 0% Neu 0% Pos 77.1%

Comments

No comments yet. Be the first!